NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,037,061.60 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 32,612 shares of the business’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. This represents a 57.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, January 27th, Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.62, for a total value of $1,298,797.92.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.78, for a total value of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total value of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $31.12 on Friday. The company has a 50 day simple moving average of $35.05 and a 200 day simple moving average of $31.38. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The firm has a market cap of $3.53 billion, a PE ratio of -15.18 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC lifted its position in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares in the last quarter. Mather Group LLC. bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in NewAmsterdam Pharma during the 3rd quarter worth about $30,000. Wolverine Asset Management LLC bought a new position in NewAmsterdam Pharma in the 3rd quarter worth about $69,000. Finally, NBC Securities Inc. purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at about $86,000. Institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the subject of several research analyst reports. The Goldman Sachs Group lifted their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Royal Bank Of Canada upped their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Citigroup raised their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, HC Wainwright assumed coverage on NewAmsterdam Pharma in a report on Monday, October 20th. They issued a “buy” rating and a $52.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.